Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Dow
Mallinckrodt
McKinsey
Merck

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 10,239,927

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,239,927
Title:Peptides and compositions for treatment of joint damage
Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
Inventor(s): Johnson; Kristen (San Diego, CA), Shi; Jian (San Diego, CA)
Assignee: Novartis AG (Basel, CH)
Application Number:15/660,914
Patent Claims:1. A method of treating or ameliorating arthritis or articular cartilage damage in a subject, the method comprising administering to a joint of the subject a therapeutically effective amount of a polypeptide comprising SEQ ID NO: 28.

2. The method of claim 1, wherein the subject has arthritis, and wherein the arthritis is osteoarthritis, trauma arthritis, or autoimmune arthritis.

3. The method of claim 1, further comprising administering to the subject one or more additional chondrogenic factors.

4. The method of claim 1, further comprising administering to the subject hyaluronic acid or a derivative thereof.

5. The method of claim 1, further comprising administering to the subject an agent selected from the group consisting of oral salmon calcitonin, SD-6010 (iNOS inhibitor), vitamin D3 (choliecalciferol), collagen hydrolyzate, FGF18, BMP7, rusalatide acetate, avocado soy unsaponifiables (ASU), kartogenin, a steroid, and a non-steroidal anti-inflammatory agent (NSAID).

6. The method of claim 1, further comprising performing a surgical procedure on an affected joint in a subject.

7. The method of claim 6, wherein administering the polypeptide occurs during or after the surgical procedure.

8. The method of claim 1, wherein administering the polypeptide occurs in conjunction with any one of bone marrow stimulation, cartilage replacement, autologous chondrocyte implantation (ACI), matrix-induced autologous chondrocyte implantation (MACI).

9. The method of claim 1, wherein administering the polypeptide occurs in conjunction with autologous chondrocyte implantation (ACI).

10. The method of claim 1, wherein the polypeptide is administered in a matrix or biocompatible scaffold.

11. The method of claim 1, further comprising determining the expression level of a hyaline cartilage-specific protein in the joint before and after administering the polypeptide, wherein the hyaline cartilage-specific protein is type II collagen or aggrecan.

12. The method of claim 11, wherein the expression level of the hyaline cartilage-specific protein is determined by immunohistochemistry, immunocytochemistry, or PCR.

13. The method of claim 1, further comprising determining the expression level of a fibrotic cartilage-specific protein in the joint before and after administering the polypeptide, wherein the fibrotic cartilage-specific protein is type X collagen.

14. The method of claim 13, wherein the expression level of the fibrotic cartilage-specific protein is determined by immunohistochemistry, immunocytochemistry, or PCR.

15. A method of inducing differentiation of mesenchymal stem cells into chondrocytes, the method comprising contacting mesenchymal stem cells with an effective amount of a polypeptide comprising SEQ ID NO: 28.

16. The method of claim 15, wherein the method is performed in vivo and the stem cells are present in a human subject.

17. The method of claim 16, wherein the subject has arthritis or cartilage damage.

18. The method of claim 17, wherein the arthritis is osteoarthritis, trauma arthritis, or autoimmune arthritis.

19. The method of claim 16, further comprising administering to the subject one or more additional chondrogenic factors.

20. The method of claim 16, further comprising administering to the subject an agent selected from the group consisting of hyaluronic acid or a derivative thereof, oral salmon calcitonin, SD-6010 (iNOS inhibitor), vitamin D3 (choliecalciferol), collagen hydrolyzate, FGF18, BMP7, rusalatide acetate, avocado soy unsaponifiables (ASU), kartogenin, a steroid, and a non-steroidal anti-inflammatory agent (NSAID).

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
McKinsey
Baxter
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.